• Werewolf Therapeutics director Luke Evnin reported sales of 205,911 common shares on April 27-29.
• Shares were sold at weighted average prices of $0.85, $0.73, $0.69.
• Beneficial ownership fell to 1,953,949 shares following April 29 transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001134657-26-000007), on April 29, 2026, and is solely responsible for the information contained therein.